Zobrazeno 1 - 10
of 1 978
pro vyhledávání: '"Kullak-Ublick"'
Autor:
Sophia L. Samodelov, Zhibo Gai, Francesca De Luca, Klara Haldimann, Sven N. Hobbie, Daniel Müller, Gerd A. Kullak-Ublick, Michele Visentin
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Colistin is a polymyxin antibiotic currently experiencing renewed clinical interest due to its efficacy in the treatment of multidrug resistant (MDR) bacterial infections. The frequent onset of acute dose-dependent kidney injury, with the po
Externí odkaz:
https://doaj.org/article/a51caf5e8b014775b1788ea24ca7f003
Autor:
Andreas Trojan, Emanuele Laurenzi, Stephan Jüngling, Sven Roth, Michael Kiessling, Ziad Atassi, Yannick Kadvany, Meinrad Mannhart, Christian Jackisch, Gerd Kullak-Ublick, Hans Friedrich Witschel
Publikováno v:
Frontiers in Digital Health, Vol 6 (2024)
BackgroundThe use of smartphone apps in cancer patients undergoing systemic treatment can promote the early detection of symptoms and therapy side effects and may be supported by machine learning (ML) for timely adaptation of therapies and reduction
Externí odkaz:
https://doaj.org/article/b73687fc63bc423ea85ada7bc1ad7170
Autor:
Seth Duwor, Katharina Enthofer, Christoph Ganter, Prabin Poudel, Anna Svarin, Gerd A. Kullak-Ublick
Publikováno v:
Pharmacoepidemiology, Vol 3, Iss 1, Pp 33-50 (2024)
Introduction: Calcineurin inhibitors (CNIs), ciclosporin and tacrolimus, are utilized primarily in organ transplantation and the treatment of autoimmune diseases. Since patients depend on these drugs over long periods, they face a potential risk of i
Externí odkaz:
https://doaj.org/article/cff3d84d5787481db17d8967cc6c97e9
Autor:
Andreas Trojan, Christian Kühne, Michael Kiessling, Johannes Schumacher, Stefan Dröse, Christian Singer, Christian Jackisch, Christoph Thomssen, Gerd A Kullak-Ublick
Publikováno v:
JMIR Formative Research, Vol 8, p e55917 (2024)
BackgroundThe evaluation of electronic patient-reported outcomes (ePROs) is increasingly being used in clinical studies of patients with cancer and enables structured and standardized data collection in patients’ everyday lives. So far, few studies
Externí odkaz:
https://doaj.org/article/869aa6dfcdec43b9ab44d038d3dac136
Autor:
Andreas Trojan, Sven Roth, Ziad Atassi, Michael Kiessling, Reinhard Zenhaeusern, Yannick Kadvany, Johannes Schumacher, Gerd A Kullak-Ublick, Matti Aapro, Alexandru Eniu
Publikováno v:
JMIR Cancer, Vol 10, p e54178 (2024)
BackgroundTrastuzumab has had a major impact on the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). Anti-HER2 biosimilars such as Ogivri have demonstrated safety and clinical equivalence to trastuzumab (using
Externí odkaz:
https://doaj.org/article/93eadb61cfc44112ad034c037c1f76ca
Autor:
Lucena, M.I., Villanueva-Paz, M., Alvarez-Alvarez, I., Aithal, G.P., Björnsson, E.S., Cakan-Akdogan, G., Cubero, F.J., Esteves, F., Falcon-Perez, J.M., Fromenty, B., Garcia-Ruiz, C., Grove, J.I., Konu, O., Kranendonk, M., Kullak-Ublick, G.A., Miranda, J.P., Remesal-Doblado, A., Sancho-Bru, P., Nelson, L., Andrade, R.J., Daly, A.K., Fernandez-Checa, J.C.
Publikováno v:
In Pharmacological Research February 2024 200
Autor:
Jane I. Grove, Camilla Stephens, M. Isabel Lucena, Raúl J. Andrade, Sabine Weber, Alexander Gerbes, Einar S. Bjornsson, Guido Stirnimann, Ann K. Daly, Matthias Hackl, Kseniya Khamina-Kotisch, Jose J. G. Marin, Maria J. Monte, Sara A. Paciga, Melanie Lingaya, Shiva S. Forootan, Christopher E. P. Goldring, Oliver Poetz, Rudolf Lombaard, Alexandra Stege, Helgi K. Bjorrnsson, Mercedes Robles-Diaz, Dingzhou Li, Thi Dong Binh Tran, Shashi K. Ramaiah, Sophia L. Samodelov, Gerd A. Kullak-Ublick, Guruprasad P. Aithal, on behalf of the TransBioLine consortium
Publikováno v:
Diagnostic and Prognostic Research, Vol 7, Iss 1, Pp 1-15 (2023)
Abstract A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative’s TransBioLine consor
Externí odkaz:
https://doaj.org/article/01c9031ea63844faa64609c76d355eda
Autor:
M.I. Lucena, M. Villanueva-Paz, I. Alvarez-Alvarez, G.P. Aithal, E.S. Björnsson, G. Cakan-Akdogan, F.J. Cubero, F. Esteves, J.M. Falcon-Perez, B. Fromenty, C. Garcia-Ruiz, J.I. Grove, O. Konu, M. Kranendonk, G.A. Kullak-Ublick, J.P. Miranda, A. Remesal-Doblado, P. Sancho-Bru, L. Nelson, R.J. Andrade, A.K. Daly, J.C. Fernandez-Checa
Publikováno v:
Pharmacological Research, Vol 200, Iss , Pp 107046- (2024)
In the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded futur
Externí odkaz:
https://doaj.org/article/2c7c8e11fae04b7f942b7aa0a4dabc81
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.